Particularly, the octavalent tetra-specific CD19xCD3x4-1BBxPD-L1 antibody emfizatamab is currently developed to target CD19+ lymphoma and leukemia cells by the engagement and activation of T cells via their CD3 and 4-1BB receptors, while also preventing tumor T cell inhibition by blocking PD-L1 (NCT04606433) (159, 160). Here, CD274 is linked to neoplasm.